Tailored IV fluids aim to shield kidneys during heart tests

NCT ID NCT04936607

Recruiting now Prevention Sponsor: Montreal Heart Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized hydration strategy to prevent contrast-induced acute kidney injury (CI-AKI) in adults undergoing coronary angiogram or PCI. Participants receive intravenous saline at rates adjusted based on their heart pressure, contrast dose, and kidney function. The goal is to see if this tailored approach reduces kidney damage and improves overall outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Personalized hydration strategy (intravenous saline adjusted based on heart pressure, contrast dose, and kidney function)
What this could lead to: If successful, this could provide a simple, tailored hydration method to reduce the risk of kidney injury after common heart procedures.
What could go wrong: This is an early-stage trial (Phase NA) with 1158 participants, so results may not apply to all patients. The hydration adjustments are complex and may not prevent kidney injury in everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRAST INDUCED ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTRAST INDUCED ACUTE KIDNEY INJURY

Contacts and locations

Locations

Montreal Heart Institute
RECRUITING

Montreal, Quebec, H1T1C8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.